Why is MDXG down?
Down 16% on Nov 2, and still 21% under its Oct 30 close.
- MiMedx fell 16% that day while medical device stocks rose a median 0.8%:
−3Long-term trend
Down 16% on Nov 2, and still 21% under its Oct 30 close.
−3Long-term trend
MDXG's Quality Score rose 1 point on Fri, Nov 20, to -6. It had its calmest day in a week.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2024 high | Down 68% |
| Latest filing | 8-K, Oct 28 |
Expected to report Wed Feb 24, after the close
MDXG is #84 of 86 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 84 |
Expected to report Wed Feb 24, after the close (in 95 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The year-over-year decline in gross margin was driven primarily by the Medicare reimbursement rules negatively impacting the prices of our Wound products along with unfavorable product mix.”
MDXG gives its mix in its presentation's charts, not in a table we read.
| Measure | Figure |
|---|---|
| Net sales | $250M to $260M |
“The Company expects Adjusted EBITDA for the fourth quarter to be sequentially higher than the third quarter.”
From its results filing (SEC filing · Oct 28)
Sales grew 11% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 6.7% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 28, 2026 | -8.3% | +0.5% | -19.0% |
| Jul 29, 2026 | -7.8% | +0.9% | -1.6% |
| Apr 29, 2026 | -1.1% | +8.9% | +18.6% |
| Feb 25, 2026 | -0.8% | -6.4% | -8.7% |
Sales grew in four of the last seven years, to $419M in 2025. It made a profit in three of the eight years.
RSI 22.0, MACD above signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: MDXG is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
“Due to lower barriers to entry in the Section 361 HCT/P regulated market, competition is intense in the skin substitute market, particularly among human-derived products and subject to new entrants and evolving market dynamics.”
MDXG scores -6 today, which Breakaway calls Poor. It is #84 of 86 in Medical Devices by Quality Score, with 1 of 14 chart checks firing. Down 16% on Nov 2, and still 21% under its Oct 30 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
MDXG scores -6 today, which Breakaway calls Poor (below zero). That is #84 of 86 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MDXG's -6.
Expected to report Wed Feb 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. MDXG closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.